The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Single nucleotide polymorphisms (SNPs) and circulating endothelial cells (CECs) as outcome predictors in patients (pts) with recurrent glioblastoma (rGBM) treated with bevacizumab (BEV) and sorafenib (SOR).
S. K. Anderson
No relevant relationships to disclose
J. M. Lafky
No relevant relationships to disclose
X. W. Carrero
No relevant relationships to disclose
T. K. Kimlinger
No relevant relationships to disclose
T. M. Halling
No relevant relationships to disclose
S. Kumar
Consultant or Advisory Role - Merck (U)
Honoraria - Merck
Research Funding - Celgene; Genzyme; Millennium; Novartis
P. J. Flynn
Consultant or Advisory Role - Genentech
Honoraria - Genentech
H. M. Gross
No relevant relationships to disclose
K. A. Jaeckle
No relevant relationships to disclose
J. C. Buckner
No relevant relationships to disclose
E. Galanis
No relevant relationships to disclose